BUZZ-Tekmira Pharmaceuticals Corp: Maxim Group raises price target

Fri Oct 3, 2014 8:24am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

** Drug developer's shares up 6.1 pct at $26.59 premarket

** Maxim Group raises price target on Tekmira's U.S.-listed stock to $31 from $23, gives a "buy" rating

** Company announced development milestone, supporting a $1.5 million payment from Monsanto Co

** Company agreed on Jan. 13 to license its delivery technology for use by Monsanto's agricultural applications

** Of five analysts covering Tekmira stock, three have "strong buy" ratings and two have "buy" ratings

** Median price target on stock is $25, according to Thomson Reuters data

** Up to Thursday's close, shares more than tripled in value this year